dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English

18.10.2018: Novaliq GmbH

NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR ITS CYCLASOL® PHASE 2b/3 ESSENCE TRIAL IN PATIENTS WITH DRY EYE DISEASE


Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces positive topline results from ESSENCE, its first pivotal clinical trial of CyclASol® 0.1% for the treatment of dry eye disease (DED).

Den gesamten Artikel lesen Sie bitte hier

News 2018, Novaliq GmbH
18.10.2018: Cassiopea SpA
18.10.2018: Apogenix AG

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz